Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2009-05-11
2010-11-09
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S139100, C424S141100, C514S885000
Reexamination Certificate
active
07829094
ABSTRACT:
Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1β binding antibody or IL-1β binding fragment thereof. An IL-1β binding antibody or IL-1β binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO: 15 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency.
REFERENCES:
patent: 4762914 (1988-08-01), Auron et al.
patent: 4766069 (1988-08-01), Auron et al.
patent: 4772685 (1988-09-01), Schmidt et al.
patent: 4935343 (1990-06-01), Allison et al.
patent: 5001057 (1991-03-01), Auron et al.
patent: 5077219 (1991-12-01), Auron et al.
patent: 5122459 (1992-06-01), Conlon et al.
patent: 5286847 (1994-02-01), Gehrke et al.
patent: 5348858 (1994-09-01), Uetsuki et al.
patent: 5474899 (1995-12-01), Lisi
patent: 5484887 (1996-01-01), Kronheim et al.
patent: 5510462 (1996-04-01), Auron et al.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5681933 (1997-10-01), Auron et al.
patent: 5766886 (1998-06-01), Studnicka et al.
patent: 5789185 (1998-08-01), Lisi
patent: 5869619 (1999-02-01), Studnicka
patent: 5885793 (1999-03-01), Griffiths
patent: 5959085 (1999-09-01), Garrone et al.
patent: 6864047 (2005-03-01), Donovan et al.
patent: 6899878 (2005-05-01), Graham et al.
patent: 7531166 (2009-05-01), Masat et al.
patent: 2003/0022869 (2003-01-01), Wiemer et al.
patent: 2003/0026806 (2003-02-01), Witte et al.
patent: 2003/0124617 (2003-07-01), Gram et al.
patent: 2003/0166069 (2003-09-01), Welcher et al.
patent: 2004/0023869 (2004-02-01), Sims et al.
patent: 2004/0063913 (2004-04-01), Gram et al.
patent: 2005/0084493 (2005-04-01), Witte
patent: 2005/0152850 (2005-07-01), Engebretson
patent: 2005/0186615 (2005-08-01), Lin et al.
patent: 2005/0256197 (2005-11-01), Engebretson
patent: 2006/0094663 (2006-05-01), Chemtob
patent: 2009/0060918 (2009-03-01), Masat et al.
patent: 2009/0060923 (2009-03-01), Masat et al.
patent: 0267611 (1993-05-01), None
patent: 0161 901 (1993-12-01), None
patent: 0364778 (1996-03-01), None
patent: 0569687 (2002-08-01), None
patent: 95/01997 (1995-01-01), None
patent: 0216436 (2002-02-01), None
patent: 0216436 (2002-02-01), None
patent: 03/010282 (2003-02-01), None
patent: 03/034984 (2003-05-01), None
patent: 03/073982 (2003-09-01), None
patent: 2004002512 (2004-01-01), None
patent: 2004/067568 (2004-08-01), None
patent: 2004/072116 (2004-08-01), None
patent: 2005019259 (2005-03-01), None
patent: 2005084696 (2005-09-01), None
patent: 2006/081139 (2006-08-01), None
patent: 2007002261 (2007-01-01), None
patent: 2004022718 (2008-06-01), None
Beers and Berkow (1999). The Merck Manual of Diagnosis and Therapy, 17thedition, pp. 965-969.
Kozak, et al. IL-6 and IL-1 beta in fever: studies using cytokine-deficient (knockout) mice, Annals of the New York Academy of Sciences 856:33-47 (1998).
Kuhns, et al., Ca2+-Dependent Production and Release of IL-3 in Human Neutrophils. J. Immuno.161(8): 4332-39 (1998).
Larsen et al, Interleukin-1-receptor antagonist in type 2 diabetes mellitus, New England Journal of Medicine, 356:1517-1526 (2007).
Ledingham, et al., Nitric oxide donors stimulate prostaglandin F2a and inhibit thromboxane B2 production in the human cervix during the first trimester of pregnancy. Mol. Hum. Reprod. 5(10): 973-82 (1999).
Levesque, et al., Activated T Lymphocytes Regulate Hyaluronan Binding to Monocyte CD44 Via Production of IL-2 and IFN-y. J, Immuno. 166 (1): 188-96 (2001).
Li et al., Expression of caspase-1 in synovial membrane-like interface tissue around loosened hip prostheses. Rhem. Int. 22: 97-102 (2002).
Lichtman AH, et al., Role of interleukin 1 in the activation of T lymphocytes. PNAS 85:9699-9703 (1988.
Lin, et al., Pseudomonas aeruginosa Activates Human Mast Cells to Induce Neutrophil Transendothelial Migration Via Mast Cell-Derived IL-1a and Beta. J. Immuno. 169 : 4522-30 (2002).
Lipsky PE, Rheumatoid arthritis. In: Harrison's principles of internal medicine. Wilson J, Braunwald E, Isselbacher K, et al., eds, McGraw-Hili, Inc. 313: 1880-1888 (1998).
Liu-Bryan, et al., Innate Immunity Conferred by Toll-like Receptors 2 and 4 and Myeloid Differentiation Factor Expressionis Pivotal to Monosodium Urate Monohydrate Crystal-induced Inflammation, Arthritis & Rheumatism 52 (9):2936-46 (2005).
Liu-Bryan, et al., TLR2 Signaling in Chondrocytes Drives Calcium Pyrophosphate Dihydrate and Monosodium Urate Crystal-Induced Nitric Oxide Generation, J. Immunology 174:5016-5023 (2005).
Lovell OJ, et al., Preliminary evidence for bioactivity of IL-1 trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis (sJIA). Arthritis and Rheumatism 54(9) (2006).
Lovell, et al., Interleukin-1 blockade by anakinra improves clinical systems in patients with neonatal-onset multisystem inflammatory disease, Arthritis and Rheumatism 52(4):1283-86 (2005).
Lu et al., IL-1 beta epitope mapping using site-directed mutagenesis and hydrogen-deuterium exchange mass spectrometry analysis. Biochemistry 44:11106-11114 (2005).
Maedler et al, Glucose-induced B cell production of IL-1 B contributes to glucose toxicity in human pancreatic islets, J Clin Invest 110:851-860 (2002).
Maedler et al., Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1 beta in human islets. Proc. Natl. Acad. Sci. USA 101:8138-8143 (2004).
Marovich, D et al., IL-12p70 Production by Leishmania major-Harboring Human Dendritic Cells Is a CD40/CD40 Ligand-Dependent Process. J. Immuno. 164(11): 5658-65 (2000).
Marovich, et al., IL-12p70 Production by Leishmania major-Harboring Human Dendritic Cells Is a CD40/CD40 Ligand-Dependent Process. J. Immuno. 164(11): 5658-65 (2000).
Martinon F, et al., Gout-associated uric acid crystals activate the nalpinflammasome. Nature 440(9):237-41 (2006).
Martinon, et al., Gout associated uric-acid crystals activate the NALP3 inflammasome, Nature 440:237-241 (2006).
Martinon, et al., Gout: New insights into an old disease, J. Clin. Invest. 116:2073-2075 (2006).
Massone, et al., Mapping of Biologically Relevant Sites of Human IL-1 ˜ Using Monoclonal Antibodies. J.Immuno. 140(11):3812-3816 (1988).
Matsuzawa, The metabolic syndrome and adipocytokines, FEBS Lett. 580:2917-2921 (2006).
Maybee, et al., Is anti-inflammatory therapy for type-2 diabetes mellitus ready for routine clinical practice?, Nature Clinical Practice, 3(12): 806-7 (2007).
Mayfield, Diagnosis and classification of diabetes mellitus: new criteria. Am Fam Physician 58:1355-62 (1998).
McGonagle, et al., Management of treatment resistent inflammation of acute on chronic tophaceous gout with anakinra, Ann. Rheum. Dis. 66:1683-1684 (2007).
McIntyre et al., Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J. Exp. Med. 173:931-939 (1991).
Mellgren et al., The renal subcapsular site offers better growth conditions for transplanted mouse pancreatic islet cells than the liver or spleen, Diabetologia 29:670-2 (1986).
Moldovan, et al., Diacerhein and rhein reduce the ICE-induced IL-1Beta and IL-1Beta activation in human osteoarthritic cartilage. Osteoarthritis and Cartilage, 8:186-96 (2000).
Morisaki, et al., A combination of Cyclosporin-A (CsA) and InterferonGamma (INF-y) Induces Apoptosis in Human Gastric Carcinoma Cells. Anticancer Research. 20: 3363-74 (2000).
Napoleone, et al., Monocytes Upregulate Endothelial Cell Expression of Tissue Factor: A Role for Cell-Cell Contact and Cross-Talk. Blood 89(2) 541-9 (1997).
Nathan, Thiazolidinediones for initial treatment of type 2 diabetes? N. Engl. J. Med. 355:2477-2480 (2006).
Nicoletti, et al., Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor, Eur J Immunol24:
Chen Gang
Haak-Frendscho Mary
Horwitz Arnold H.
Masat Linda
Roell Marina
K&L Gates LLP
Mertz Prema
Polo John
Xoma Technology Ltd.
LandOfFree
Method of treating an IL-1 related cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating an IL-1 related cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating an IL-1 related cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4158572